SIRNAOMICS-B (02257) surged over 9% during intraday trading, with cumulative gains exceeding 530% year-to-date. As of press time, the stock was up 7.27% to HK$22.12, with trading volume reaching HK$33.02 million.

SIRNAOMICS recently announced a share placement to four investors, including Huaxi Biological Technology (Hong Kong), at a 19.84% discount, totaling 17.3524 million new shares. Huaxi Biological (688363.SH) stated that it invested approximately 138 million yuan through its wholly-owned subsidiary to subscribe to the strategic placement shares of SIRNAOMICS. Upon completion of the placement, the company will hold approximately 9.44% stake in SIRNAOMICS.

According to reports, this investment by Huaxi Biological aims to advance SIRNAOMICS' research and development and commercialization processes in medical aesthetics, aging intervention, and regenerative medicine fields. The company will allocate substantial resources particularly toward the STP705 targeted fat reduction project and other siRNA-based medical aesthetics pipeline assets, including clinical development expertise and commercialization capabilities in Greater China and globally.